Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Matches the labeled indication and core administration/dosing concept (severe hypoglycemia; diabetes; age threshold ≥6; subcutaneous autoinjector; 0.6 mg with possible second dose after 15 minutes) but several additional claims are not directly supported by the supplied label excerpts (e.g., unconsciousness/oral sugar criteria, mechanistic wording, and general “fast onset” guidance).
Category Scores
Accurate Statements
Zegalogue is an autoinjector medicine used for the treatment of severe hypoglycemia in people with diabetes.
Indication: "ZEGALOGUE® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above." (1 INDICATIONS AND USAGE)
The autoinjector is meant to be activated promptly according to the instructions provided with the product.
Administration instruction: "Administer ZEGALOGUE as soon as possible when severe hypoglycemia is recognized." and "Administer ZEGALOGUE according to the printed instructions... and the Instructions For Use." (2.1)
Zegalogue’s active ingredient (zogloza) works by raising blood glucose during an episode of severe hypoglycemia.
Mechanism: "increases blood glucose concentration... stimulating glycogen breakdown and release of glucose from the liver" and clinically "treating hypoglycemia" (12.1 and 1 INDICATIONS AND USAGE)
Because severe hypoglycemia can recur, caregivers typically administer Zegalogue immediately and then follow up with medical guidance.
Label includes: "Call for emergency assistance immediately after administering the dose." and instructs caregiver administration "as soon as possible" when recognized. (2.1)
Unsupported Statements
Zegalogue is used for severe hypoglycemia when a person cannot take oral sugar or is unconscious.
The supplied label excerpts do not state criteria such as inability to take oral sugar or unconsciousness as the labeled indication trigger.
Zegalogue’s active ingredient (zogloza) works by raising blood glucose during an episode of severe hypoglycemia.
While the mechanism supports raising blood glucose generally, the excerpted label does not explicitly tie the mechanistic statement to the specific scenario wording used in the claim (“during an episode of severe hypoglycemia”) as a stated label phrasing.
Zegalogue is designed for quick, emergency use.
The excerpts specify administer "as soon as possible" and emergency assistance after dosing, but do not explicitly describe the product as "designed for quick, emergency use."
For emergency glucose-raising injections, onset is generally targeted to be fast enough to stabilize the person while additional care is arranged.
The supplied excerpts discuss efficacy endpoint "time to plasma glucose recovery" but do not provide explicit "onset targeted" language to stabilize the person while additional care is arranged.
Exact timing of onset can vary by patient and episode.
The supplied excerpts provide trial time-to-recovery outcomes but do not explicitly state variability of onset by patient and episode.
Specific time-to-effect guidance depends on the approved product labeling.
This is a general meta-statement and is not supported or specified within the provided label excerpts.
Zegalogue’s active ingredient (zogloza) works by raising blood glucose during an episode of severe hypoglycemia.
The mechanism excerpt supports raising blood glucose via hepatic glycogen breakdown, but the claim implies an episode-specific framing that is not explicitly stated in the provided excerpts.
Contradictions
Important Omissions
Age indication detail (must be "aged 6 years and above" for pediatric/adult patients).
Importance:
Moderate
Dose specificity (0.6 mg subcutaneous) and the label’s repeat-dose rule (additional 0.6 mg if no response after 15 minutes, from a new device).
Importance:
Moderate
Route limitation ("subcutaneous injection only").
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Claims about urgency/administration are broadly consistent, but unsupported statements (e.g., unconsciousness/oral sugar criteria; generalized “quick/emergency” and “onset targeted”) and omissions of age threshold, explicit 0.6 mg dosing, SC-only route, and the 15-minute repeat-dose instructions could lead to incomplete or inaccurate use if relied upon without label details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not directly supported by the provided label excerpts, and key labeled specifics (age ≥6, 0.6 mg SC, repeat dose after 15 minutes from new device) were omitted.
Suggested Improvement
Restrict descriptions to label-supported points: indicate severe hypoglycemia in diabetes patients aged ≥6; state subcutaneous injection only; specify 0.6 mg dose and repeat 0.6 mg if no response after 15 minutes using a new device; avoid adding criteria like unconsciousness/oral-sugar inability and avoid unsupported general “onset targeted” phrasing.